Inclusion Criteria:

- Histologically or cytologically confirmed adenocarcinoma of the male or female breast
(male or female) with gross, uncontrolled, unresectable breast and/or chest wall
disease including:

1. patients with locally advanced unresectable stage IIIa or IIIb;

2. patients with locally recurrent (including locoregional lymph nodes) disease for
which curative surgery is not thought possible

3. patients with metastatic disease AND uncontrolled locoregional disease are
eligible.

- Prior chemotherapy allowed, except for nitrosoureas and mitomycin chemotherapy or
high dose chemotherapy with marrow or stem cell rescue.

- Prior palliative radiation to sites of metastases allowed (i.e. bone, brain, lung)

- 4 weeks since any prior treatments (excluding hormonal therapy). Concurrent hormonal
therapy is not allowed.

- Aged 18 years or older

- CALGB performance status of 0 - 2

- Life expectance of at least 12 weeks

- Initial Laboratory Data:

- ANC Count > 1500/mm3

- Platelet Count > 100,000/mm3

- Creatine ≤ 2.0 mg/dl

- Bilirubin ≤ 1.5 mg/dl

- ALT (SGPT) ≤ 3 times the upper limit of normal

- Signed informed consent

Exclusion Criteria:

- Prior breast or chest wall radiation is not allowed unless the proposed site
radiation port does not overlap with prior ports

- Subjects must not be pregnant (females able to have children must have negative
pregnancy test and agree to use adequate contraception)

- Patients with a documented hypersensitivity to E.coli derived proteins are excluded.

- No other serious medical condition such as uncontrolled infection that in the opinion
of the investigators places patient at undue risk for study treatment